Condition

Pulmonary Hypertension Due to Lung Diseases

ClinicalTrials.gov condition label

Clinical trials4

Recruiting2

Common interventions4

Lead sponsors shown4

Clinical trials

4 shown

Collagen Fingerprinting for Stratification of Pulmonary Hypertension (PH) PatientsNCT07498244 · 2026-07-01

RECRUITING

Bioenergetic Effect of Pioglitazone in CLD-PHNCT06336798 · 2024-12-17

RECRUITING

Longitudinal Outcomes of Patients With Group 3 Pulmonary Hypertension Treated With IloprostNCT07478094 · 2026-05-01

COMPLETED

A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILDNCT04691154 · 2021-08-01

ACTIVE_NOT_RECRUITING

Common interventions

L606 inhalation suspensionCOMBINATION_PRODUCT1LabsDIAGNOSTIC_TEST1Pioglitazone 30mgDRUG1PlaceboDRUG1

Leading sponsors

Emory University1Liquidia Technologies, Inc.1Medical University of Graz1University of Sao Paulo General Hospital1

Trial status mix

RECRUITING2

ACTIVE_NOT_RECRUITING1

COMPLETED1

Phase mix

PHASE21

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.